2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-12153
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # MM0070-7D24
Format
Azide and BSA Free
Concentration
LYOPH mg/ml
Product Summary for 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
Immunogen
Human recombinant 2B4/CD244/SLAMF4 (extracellular domain)
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
Western Blot: 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) [NBP2-12153]
Applications for 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
Application
Recommended Usage
Immunohistochemistry
1:50-1:200
Western Blot
1:500-1:1000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Reconstitution
Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml.
Formulation
Lyophilized from a 0.2 um filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: 2B4/CD244/SLAMF4
The 2B4 receptor has both activating and inhibitory signaling properties (1,4). 2B4's ligand is CD48, which is expressed on hematopoietic cells (4, 5). When bound to CD48, subsequent phosphorylation of the ITSMs occurs, followed by recruitment of SH-2-containing adaptor protein (SAP) and Fyn, leading to phosphorylation of PLCgamma and Vav1, and resulting in NK cell activation (4). In the absence of SAP, Src homology region 2-containing protein tyrosine phosphatases (SHP) get recruited and inhibits NK cell activation (4). In the context of infection such as Epstein-Barr virus (EBV), when lacking SAP, 2B4 has been shown to have an inhibitory function via impaired T cell cytotoxicity against EBV-infected cells (6). While 2B4 has a role in eliciting CD8+ T cell response, overexpression of 2B4 can lead to T cell exhaustion in states of chronic infection (6). Studies have suggested that the antibody blockade of the 2B4-CD48 interaction might enhance T cell and NK cell function, however given both the activating and inhibitory properties of the 2B4 receptor, more research needs to be done to prevent unwanted effects (6).
References
1. Buller CW, Mathew PA, Mathew SO. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers (Basel). 2020 Jul 1;12(7):1755. https://doi.org/10.3390/cancers12071755
2. Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal. 2017;15(1):1. https://doi.org/10.1186/s12964-016-0160-z
3. Uniprot (Q9BZW8)
4. Chen Y, Lu D, Churov A, Fu R. Research Progress on NK Cell Receptors and Their Signaling Pathways. Mediators Inflamm. 2020 Jul 24;2020:6437057. https://doi.org/10.1155/2020/6437057.
5. Pahima H, Puzzovio PG, Levi-Schaffer F. 2B4 and CD48: A powerful couple of the immune system. Clin Immunol. 2019 Jul;204:64-68. https://doi.org/10.1016/j.clim.2018.10.014.
6. Waggoner SN, Kumar V. Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front Immunol. 2012;3:377. https://doi.org/10.3389/fimmu.2012.00377
Additional 2B4/CD244/SLAMF4 Products
Product Documents for 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
Product Specific Notices for 2B4/CD244/SLAMF4 Antibody (MM0070-7D24) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...